Xiong Z Ruan Selected Research

Caseins (Casein)

1/2016	Inflammatory Stress Sensitizes the Liver to Atorvastatin-Induced Injury in ApoE-/- Mice.
10/2015	Paradoxical effect of rapamycin on inflammatory stress-induced insulin resistance in vitro and in vivo.
5/2015	Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice.
1/2014	Inflammatory stress increases hepatic CD36 translational efficiency via activation of the mTOR signalling pathway.
12/2013	Chronic inflammation exacerbates glucose metabolism disorders in C57BL/6J mice fed with high-fat diet.
5/2012	Inflammatory stress exacerbates hepatic cholesterol accumulation via disrupting cellular cholesterol export.
10/2011	Inflammatory stress exacerbates lipid-mediated renal injury in ApoE/CD36/SRA triple knockout mice.
6/2011	Inflammatory stress exacerbates ectopic lipid deposition in C57BL/6J mice.
5/2011	Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis.
9/2008	Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiong Z Ruan Research Topics

Disease

25	Inflammation (Inflammations) 01/2022 - 01/2003
13	Non-alcoholic Fatty Liver Disease 01/2022 - 09/2008
7	Atherosclerosis 06/2021 - 07/2005
6	Insulin Resistance 01/2021 - 06/2011
6	Obesity 06/2020 - 12/2005
6	Hepatoblastoma 10/2016 - 09/2008
5	Hyperlipidemias (Hyperlipidemia) 01/2021 - 07/2005
5	Neoplasms (Cancer) 01/2021 - 12/2005
4	Chronic Renal Insufficiency 01/2021 - 12/2009
4	Fibrosis (Cirrhosis) 12/2017 - 10/2011
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 02/2014
3	Fatty Liver 01/2019 - 04/2012
2	Hypercholesterolemia 03/2022 - 01/2017
2	Metabolic Diseases (Metabolic Disease) 01/2022 - 12/2005
2	Atherosclerotic Plaque (Atheroma) 06/2021 - 01/2019
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 01/2017
2	Platelet Glycoprotein IV Deficiency 01/2020 - 01/2017
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 03/2019 - 12/2018
2	Carcinogenesis 12/2018 - 01/2017
2	Alcoholic Fatty Liver 01/2018 - 06/2017
2	Hyperglycemia 10/2015 - 12/2013
2	Vascular System Injuries 12/2009 - 08/2008
1	Hepatocellular Carcinoma (Hepatoma) 03/2022
1	Bites and Stings (Sting) 01/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Hyperphosphatemia 01/2021
1	Uremia 01/2021
1	Pathologic Processes 01/2021
1	Ulcerative Colitis 01/2019
1	Neoplasm Metastasis (Metastasis) 12/2018
1	Pneumonia (Pneumonitis) 01/2017

Drug/Important Bio-Agent (IBA)

24	LipidsIBA 01/2022 - 01/2003
15	CholesterolIBA 03/2022 - 07/2005
10	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 01/2014
10	Caseins (Casein)FDA Link 01/2016 - 09/2008
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 01/2016
5	Sirolimus (Rapamycin)FDA Link 10/2015 - 07/2005
4	ApolipoproteinsIBA 10/2016 - 07/2005
3	Nonesterified Fatty Acids (NEFA)IBA 01/2022 - 06/2011
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2012
3	Apolipoproteins E (ApoE)IBA 06/2021 - 10/2011
3	InflammasomesIBA 06/2021 - 06/2017
3	Scavenger Receptors (Scavenger Receptor)IBA 01/2021 - 10/2011
3	Insulin (Novolin)FDA Link 01/2020 - 12/2013
3	Biomarkers (Surrogate Marker)IBA 12/2017 - 05/2014
3	CytokinesIBA 05/2015 - 04/2012
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2014 - 09/2007
3	Interleukin-6 (Interleukin 6)IBA 01/2014 - 05/2011
2	Adenosine Triphosphate (ATP)IBA 01/2020 - 09/2008
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 12/2005
2	Olive OilIBA 03/2019 - 12/2018
2	Choline (Choline Chloride)IBA 10/2018 - 06/2017
2	Methionine (L-Methionine)FDA Link 10/2018 - 06/2017
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2018 - 01/2017
2	Advanced Glycation End ProductsIBA 12/2017 - 07/2011
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2017 - 12/2005
2	TOR Serine-Threonine KinasesIBA 10/2015 - 04/2014
2	Liver X ReceptorsIBA 01/2015 - 09/2008
2	LDL Receptors (LDL Receptor)IBA 01/2015 - 10/2011
2	oxidized low density lipoproteinIBA 01/2013 - 05/2012
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2012 - 09/2008
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 05/2012 - 03/2003
1	Sorafenib (BAY 43-9006)FDA Link 03/2022
1	InterferonsIBA 01/2022
1	Acyl Coenzyme A (Acyl CoA)IBA 01/2022
1	Sterol Regulatory Element Binding ProteinsIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	NF-kappa B (NF-kB)IBA 01/2022
1	SterolsIBA 06/2021
1	Polysaccharides (Glycans)IBA 01/2021
1	Small Interfering RNA (siRNA)IBA 01/2021
1	mannosyl-oligosaccharide 1,3 - 1,6-alpha-mannosidaseIBA 01/2021
1	Palmitic Acid (Hexadecanoic Acid)IBA 01/2021
1	MTOR InhibitorsIBA 01/2021
1	LigandsIBA 01/2021
1	SU 6656IBA 01/2021
1	MannosidasesIBA 01/2021
1	Cre recombinaseIBA 01/2021
1	Phosphates (Orthophosphate)IBA 01/2021
1	CalciumIBA 06/2020
1	Inositol (Myoinositol)IBA 06/2020
1	2-aminoethoxydiphenyl borateIBA 06/2020
1	Tyrosine (L-Tyrosine)FDA Link 01/2020
1	Insulin ReceptorIBA 01/2020
1	Non-Receptor Type 1 Protein Tyrosine PhosphataseIBA 01/2020
1	Purinergic P2X7 ReceptorsIBA 01/2020
1	Dietary Fats (Dietary Fat)IBA 03/2019
1	melitracen drug combination flupentixolIBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	src-Family KinasesIBA 12/2018
1	Oleic Acid (Oleate)IBA 12/2018
1	Phospholipids (Phosphatides)FDA LinkGeneric 12/2017
1	ThrombospondinsIBA 12/2017
1	Advanced Oxidation Protein Products (AOPP)IBA 12/2017
1	ThioredoxinsIBA 06/2017
1	NLR ProteinsIBA 06/2017
1	Urethane (Ethyl Carbamate)IBA 01/2017

Therapy/Procedure

1	Fat-Restricted Diet (Diet, Fat Restricted) 01/2020
1	Therapeutics 01/2019
1	Intraperitoneal Injections 01/2017